STING1 and neoplasm: In conclusion, ESYT3 was identified as a tumor suppressor and a novel radioimmune response sensitizer, which directly interacted with STING, and activated cGAS-STING pathway, subsequently enhancing the generation of type I IFNs and downstream chemokines CCL5 and CXCL10, thus improving radioimmune responses (Fig. 8).